Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Verzenios ® (abemaciclib)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
Can a Verzenios® (abemaciclib) patient receive COVID-19 vaccinations?
The use of vaccines against COVID-19 in patients treated with abemaciclib, while not contraindicated, has not been systematically studied.
Warnings and considerations for the concomitant use of COVID-19 vaccines and abemaciclib
Monitor for signs of infections and laboratory anomalies if a patient receives a vaccination before or during the abemaciclib therapy.
Please consider the risk and benefits of the vaccination on an individual patient basis.
Treatment with abemaciclib is associated with adverse reactions, such as ILD/pneumonia, neutropenia or diarrhoea, which may me important to consider when managing a patient being administered a COVID-19 vaccine or booster while concomitantly being treated with abemaciclib.1,2
For complete information, please refer to the Verzenios Summary of Product Characteristics, in particular the sections
- 4.2 Posology and method of administration
- 4.4 Special warnings and precautions for use
- 4.8 Undesirable effects
References
1Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Links to references and third-party websites are provided solely for your convenience and to facilitate easy access to the sources cited.
Date of Last Review: 24 June 2024